We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Apellis Pharmaceuticals Inc | NASDAQ:APLS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.03 | -0.06% | 47.46 | 45.00 | 48.00 | 48.76 | 47.22 | 48.46 | 1,106,739 | 21:55:33 |
Cedric Francois, CEO and co-founder of Apellis, will participate in a fireside chat at the Evercore ISI 2019 Healthcare Conference and at the Piper Jaffray 2019 Healthcare Conference.
The events will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at http://investors.apellis.com/events-and-presentations. Replays of the webcasts will be available for 90 days following the events.
About Apellis Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. For additional information about Apellis and APL-2, please visit http://www.apellis.com.
Investor Contact:Sam Martin / Maghan MeyersArgot Partnerssam@argotpartners.com / maghan@argotpartners.com212.600.1902
Media Contact:Tracy Vineis tracy.vineis@apellis.com617.420.4839
1 Year Apellis Pharmaceuticals Chart |
1 Month Apellis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions